catalym
Posted by catalym
November 15, 2021
November 15, 2021

Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment

Markus Haake, Tina Schäfer, Beatrice Haack, Neha Vashist, Sabrina Genßler, Patrick Harter,...

Read More
catalym
Posted by catalym
November 15, 2021
November 15, 2021

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Ignacio Melero, Emiliano Calvo, Maria-Elisabeth Goebeler, Elena Garralda, Reinhard Dummer, María Rodríguez-Ruiz,...

Read More
catalym
Posted by catalym
November 12, 2021
November 12, 2021

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002...

Read More